Use of Insulin Glargine to Treat Diabetic Ketoacidosis

NCT ID: NCT00179127

Last Updated: 2018-07-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-08-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children.

The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Ketoacidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glargine

0.3u/kg of glargine, subcutaneously, once

Group Type EXPERIMENTAL

glargine

Intervention Type DRUG

0.3u/kg of glargine, subcutaneously, once

Placebo

0.3u/kg of saline, subcutaneously, once

Group Type PLACEBO_COMPARATOR

saline

Intervention Type DRUG

0.3u/kg of saline, subcutaneously, once

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

glargine

0.3u/kg of glargine, subcutaneously, once

Intervention Type DRUG

saline

0.3u/kg of saline, subcutaneously, once

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with:
* Established history of insulin dependent diabetes

AND:

* Chief c/o hyperglycemia or vomiting
* Venous pH \< 7.24
* Serum Bicarbonate \< 18
* Blood glucose \> 150
* Urinary Ketones

Exclusion Criteria

* Age \< 6y.o.
* New onset diabetes
* Received IV insulin bolus prior to arrival to VCH Emergency Room (ER)
* Venous pH \> 7.24
* Serum Bicarbonate \> 18
* Pregnancy
* Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit
Minimum Eligible Age

6 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vanderbilt University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sheila McMorrow, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vanderbilt University Monroe Carell Children's Hospital

Nashville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

040643

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Children with Diabetic Ketoacidosis
NCT06599203 NOT_YET_RECRUITING
Starvation in the Treatment of Diabetic Ketoacidosis
NCT06186245 ENROLLING_BY_INVITATION NA
Dextrose Gel Does Not Prevent Neonatal Hypoglycemia
NCT02523222 COMPLETED PHASE2/PHASE3
Liver Glycogen and Hypoglycemia in Humans
NCT03241706 ACTIVE_NOT_RECRUITING PHASE1
Naloxone, Hypoglycemia and Exercise
NCT03149770 COMPLETED PHASE2